This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Rilotumumab
- DrugBank Accession Number
- DB11972
- Background
Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- AMG 102
- Rilotumumab
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Rilotumumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Rilotumumab. Aducanumab The risk or severity of adverse effects can be increased when Rilotumumab is combined with Aducanumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rilotumumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Rilotumumab. Amivantamab The risk or severity of adverse effects can be increased when Rilotumumab is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when Rilotumumab is combined with Anifrolumab. Ansuvimab The risk or severity of adverse effects can be increased when Rilotumumab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Rilotumumab. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Rilotumumab. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 51WEW898IJ
- CAS number
- 872514-65-3
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347911263
- Wikipedia
- Rilotumumab
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Terminated Treatment Malignant Neoplasm of Stomach 2 2 Completed Treatment Advanced Malignant Glioma 1 2 Completed Treatment Advanced Renal Cell Carcinoma (aRCC) 1 2 Completed Treatment Esophageal Cancer / Malignant Neoplasm of Stomach 1 2 Completed Treatment Glioblastoma Multiforme (GBM) / Gliosarcoma 1 2 Completed Treatment Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma 1 2 Withdrawn Treatment Epithelial Mesothelioma / Mesothelioma Malignant Advanced / Recurrent Malignant Mesothelioma / Sarcomatous Mesothelioma 1 2, 3 Terminated Treatment MET Positive / Recurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma AJCC v7 1 1 Completed Treatment Part 1- Advanced Solid Tumors / Part 2- Advanced or Metastatic Gastric Cancer / Part 2- Advanced or Metastatic GEJ 1 1, 2 Completed Treatment Adenocarcinomas of the Gastroesophageal Junction / Esophageal Cancer / Malignant Neoplasm of Stomach 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at October 20, 2016 21:07 / Updated at February 21, 2021 18:53